Hormone Sensitive Advanced Prostate Cancer Treatment Market

Request Methodology

Hormone Sensitive Advanced Prostate Cancer Treatment Market (2023 to 2033)

The global hormone-sensitive advanced prostate cancer treatment market is slated to reach a valuation of US$ 12.44 billion in 2023. According to Future Market Insights, the market is expected to grow at a 7.2% CAGR until 2033, valued at US$ 24.94 billion.

The primary goal of the key providers is translating science into innovative oncology medicines for helping people with cancer globally, where they commit to potentially bring new hope driving the purpose, and supporting accessibility through their cancer medicines.

Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to the recurrence or spread of cancer after initial treatment. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the United States with high-risk prostate cancer experience recurrence after localized treatment.

The prostate cancer drugs market in the United States is regulated by the FDA which is responsible for the approval of new drugs and lays down regulations related to the treatment of prostate cancer. This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market.

A new treatment is approached for prostate cancer that could stop resistance in its tracks. For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα.

North America is the largest region in the prostate cancer drugs market in 2022. The Middle East is expected to be the agile growing region in the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Attributes	Details
Projected Forecast Value (2023)	US$ 12.44 billion
Projected Forecast Value (2033)	US$ 24.94 billion
Growth rate	7.2% CAGR
Forecast period	2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Hormone Sensitive Advanced Prostate Cancer Treatment Market Historical Period 2018 To 2022 Demand Analysis Vs. Forecast 2023 to 2033

The global hormone-sensitive advanced prostate cancer treatment market grew at a CAGR of 6.6% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

The treatment landscape for patients with hormone-sensitive prostate cancer (HSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for clinicians to remain abreast of the current literature and synthesize the relevant data to inform evidence-based treatment decisions.

Although analyses encompassing men with low- and high-volume metastases failed to demonstrate a significant survival benefit for radiotherapy treatment to the prostate, new data demonstrate a benefit for men with low-volume metastatic disease. Ongoing trials will assess whether this applies to local surgical treatment. Similarly, metastasis-directed therapy appears beneficial among carefully selected patients.

New agents are constantly being developed and evaluated in the HSPC space. As mentioned above, given the advent of more recent changes in therapy for the hormonal-sensitive cancer disease, it notably uses ADT plus docetaxel as the standard of care treatment and examines the addition of darolutamide to this regimen. Given the favorable results with darolutamide in the castrate-resistant space, this may also have a role within the early HSPC realm.

Prominent Growth Drivers Influencing Hormone Sensitive Advanced Prostate Cancer Treatment Market

The increasing male geriatric population

It acts as a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to ACL (Administration for Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040. Among those populations, men are affected more by prostate cancer than women.

For example, in January 2022, according to the American Cancer Society, a US-based organization, prostate cancer develops in older men and non-Hispanic black men, and about 6 cases in 10 are diagnosed in men who are 65 or older (geriatric population). Therefore, the increasing men’s geriatric population drives the prostate cancer market.

Advancements in Cancer Detection Technology

The driving factor for the hormone-sensitive advanced prostate cancer treatment market is the advancement in technologies, personalized medicines, and cost-effective treatment procedures are some of the factors that are expected to provide a boost to the hormone-sensitive advanced prostate cancer treatment market.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What could be the Key Restraint for the Hormone Sensitive Advanced Prostate Cancer Treatment Market?

Limited Availability of Drugs

Limited commercial availability of drugs and treatments for this cancer is the challenge restraining the growth of the global hormone-sensitive prostate cancer treatment market.

The high cost associated with the treatment will obstruct the growth rate of the market. As per the American Cancer Society, prostate cancer costs on average US$ 4,300 upfront and US$ 9,100 over five years, with surgery costing US$ 15,000 upfront and US$ 19,000 over five years. Hormone therapy with radiation costs US$ 17,500 upfront and US$ 25,000 over five years. Costs for patients with advanced or metastatic prostate cancer might exceed US$ 100,000.

On the other hand, the lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the hormone-sensitive advanced prostate cancer treatment market. Additionally, lack of awareness among people and unfavorable healthcare policies will act as restraints and further impede the growth rate of the market during the forecast period.

Region-wise Analysis

What Is the Outlook of the North American Hormone Sensitive Advanced Prostate Cancer Treatment Market?

North America accounted for the largest revenue share in the hormone-sensitive advanced prostate cancer treatment market in 2022, and is expected to continue its dominance over the forecast period. This growth is attributable to a high prevalence of the disease, the presence of regional players, and favorable reimbursement policies. Changing lifestyle is another factor adding to the prevalence of diseases.

The local presence of regulatory entities in North American countries is expected to boost the development of therapies shortly. This is mainly because these entities play a pivotal role in creating awareness among people about the potential of immunotherapy in cancer management.

What Is the Outlook of Europe in Hormone Sensitive Advanced Prostate Cancer Treatment Market?

In Europe, the market for hormone-sensitive advanced prostate cancer treatment is expected to grow at a significant rate during the forecast period due to the combined efforts of several governments & private institutes, such as the European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to develop unique programs focusing on multiple approaches in drug development.

What Is the Outlook of the Asia Pacific Hormone Sensitive Advanced Prostate Cancer Treatment Market?

In Asia Pacific, the market for hormone-sensitive advanced prostate cancer treatment is expected to grow at a lucrative rate during the forecast period due to the presence of leading oncology companies and an increase in R&D investments in countries such as China and Japan.

This, in turn, has led to an increase in the development of prostate cancer drugs. Moreover, the cost of clinical trials in developing countries is lesser than that in developed countries.

Category-wise Insights

Which end-user segment is expected to gain traction from 2023 to 2033?

The demand for hospitals will be more during the forecast period.

According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.

Due to the growing number of people visiting hospitals for advice on treatment related to hormonal cancer, the hospital pharmacy is anticipated to dominate the worldwide hormone-sensitive advanced prostate cancer treatment market.

As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.

Which treatment is expected to gain traction from 2023 to 2033?

Androgen ablation therapy is said to hold a dominant share

The goal of this treatment is to reduce levels of male hormones, called androgens, in the body, or to stop them from fueling prostate cancer cell growth.

Androgens stimulate prostate cancer cells to grow. The main androgens in the body are testosterone and dihydrotestosterone (DHT). Most androgens are made by the testicles, but the adrenal glands (glands that sit above your kidneys) as well as the prostate cancer cells themselves, can also make androgens.

How Competitive Is the Market for Hormone Sensitive Advanced Prostate Cancer Treatment Market?

Some of the prominent players in the global market for Hormone Sensitive Advanced Prostate Cancer Market treatment are

Novartis Pharmaceuticals
Merc & Co., Inc.
Bristol-Myers
Dendreon Corporation
GlaxoSmithKline plc.
Ferring International Center S.A.
Roche Group
Celgen Corporation
Amgen Inc.
Teva Pharmaceutical Industries Ltd.

Some of the important developments of the key players in the market are

In March 2022, Novartis AG received USA FDA approval for Pluvicto. It is the first targeted radioligand therapy in prostate cancer, which is a type of targeted cancer treatment that combines a targeting chemical (ligand) with a therapeutic radioisotope (a radioactive particle). Reimagining medication administered via intravenous infusion for the treatment of progressive, PSMA-positive metastatic castration-resistant metastatic prostate cancer by destroying tumor cells
In June 2021, Bayer acquired Noria and PSMA Therapeutics to fulfill patients' clinical needs and broaden the metastatic prostate cancer treatment portfolio. Bayer's oncology portfolio was expanded as a result of this acquisition, which included alpha radionuclide therapy and small molecules targeting Prostate-Specific Membrane Antigen (PSMA).
In December 2020, Myovant Sciences and Pfizer announced a partnership to develop and commercialize a relugolix combination tablet for advanced metastatic prostate cancer treatment. This groundbreaking partnership considerably enhances ORGOVYX’s (relugolix) launch, as well as the future introduction of relugolix combination tablets, and increases the pipeline of potential new medications.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 7.2% from 2023 to 2033
Market value in 2023	US$ 12.44 billion
Market value in 2033	US$ 24.94 billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	US$ billion for Value and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment End-User Region
Regions Covered	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa
Key Countries Profiled	United States Canada Brazil Mexico Germany United Kingdom France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC countries South Africa Israel
Key Companies Profiled	Novartis Pharmaceuticals Merc & Co., Inc. Bristol-Myers Dendreon Corporation GlaxoSmithKline plc. Ferring International Center S.A. Roche Group Celgen Corporation Amgen Inc. Teva Pharmaceutical Industries Ltd.
Customization Scope	Available on Request

Key Segments Profiled in the Hormone Sensitive Advanced Prostate Cancer Treatment Market Report

By Treatment:

Androgen Ablation Therapy
Chemotherapy
Targeted Therapy
Cryotherapy

By End User:

Hospitals
Clinics
Cancer Rehabilitation Centers

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

Frequently Asked Questions

What is Current Market Valuation?

The market to secure a valuation US$ 12.44 billion in 2023.

How Big will be the Market by 2033?

The market is estimated to reach US$ 24.94 billion by 2033.

What is the Growth Potential of the Market?

Through 2033, the market is anticipated to expand at a 7.2% CAGR.

What was the HCAGR Market From 2018 to 2022?

From 2018 to 2022, the hormone sensitive advanced prostate cancer treatment market developed at a CAGR of 6.6%.

Which End User Segment to Grab a Considerable Share in the Market?

The market share of hospital pharmacy is projected to rise.

Which Treatment Segment to Lead the Market?

The androgen ablation therapy segment seems to dominate the market.

Table of Content

1. Executive Summary | Hormone Sensitive Advanced Prostate Cancer Treatment Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Androgen Ablation Therapy

5.3.2. Chemotherapy

5.3.3. Targeted Therapy

5.3.4. Cryotherapy

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

6.3.1. Hospitals

6.3.2. Clinics

6.3.3. Cancer Rehabilitation Centres

6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia

7.3.5. East Asia

7.3.6. Oceania

7.3.7. MEA

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. USA

8.2.1.2. Canada

8.2.2. By Treatment

8.2.3. By End User

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment

8.3.3. By End User

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment

9.2.3. By End User

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By End User

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Treatment

10.2.3. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By End User

10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Rest of South Asia

11.2.2. By Treatment

11.2.3. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By End User

11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Treatment

12.2.3. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By End User

12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. Australia

13.2.1.2. New Zealand

13.2.2. By Treatment

13.2.3. By End User

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment

13.3.3. By End User

13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MEA

14.2.2. By Treatment

14.2.3. By End User

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Treatment

14.3.3. By End User

14.4. Key Takeaways

15. Key Countries Market Analysis

15.1. USA

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2022

15.1.2.1. By Treatment

15.1.2.2. By End User

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2022

15.2.2.1. By Treatment

15.2.2.2. By End User

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2022

15.3.2.1. By Treatment

15.3.2.2. By End User

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2022

15.4.2.1. By Treatment

15.4.2.2. By End User

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2022

15.5.2.1. By Treatment

15.5.2.2. By End User

15.6. United kingdom

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2022

15.6.2.1. By Treatment

15.6.2.2. By End User

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2022

15.7.2.1. By Treatment

15.7.2.2. By End User

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2022

15.8.2.1. By Treatment

15.8.2.2. By End User

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2022

15.9.2.1. By Treatment

15.9.2.2. By End User

15.10. India

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2022

15.10.2.1. By Treatment

15.10.2.2. By End User

15.11. Malaysia

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2022

15.11.2.1. By Treatment

15.11.2.2. By End User

15.12. Singapore

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2022

15.12.2.1. By Treatment

15.12.2.2. By End User

15.13. Thailand

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2022

15.13.2.1. By Treatment

15.13.2.2. By End User

15.14. China

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2022

15.14.2.1. By Treatment

15.14.2.2. By End User

15.15. Japan

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2022

15.15.2.1. By Treatment

15.15.2.2. By End User

15.16. South Korea

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2022

15.16.2.1. By Treatment

15.16.2.2. By End User

15.17. Australia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2022

15.17.2.1. By Treatment

15.17.2.2. By End User

15.18. New Zealand

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2022

15.18.2.1. By Treatment

15.18.2.2. By End User

15.19. GCC Countries

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2022

15.19.2.1. By Treatment

15.19.2.2. By End User

15.20. South Africa

15.20.1. Pricing Analysis

15.20.2. Market Share Analysis, 2022

15.20.2.1. By Treatment

15.20.2.2. By End User

15.21. Israel

15.21.1. Pricing Analysis

15.21.2. Market Share Analysis, 2022

15.21.2.1. By Treatment

15.21.2.2. By End User

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Treatment

16.3.3. By End User

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. Novartis Pharmaceuticals

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. Merc & Co., Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. Bristol-Myers

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. Dendreon Corporation

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. GlaxoSmithKline plc.

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Ferring International Center S.A.

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Roche group

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Celgen Corporation

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Amgen Inc.

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Teva pharmaceutical Industries Ltd.

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 119: MEA Market Attractiveness by End User, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

April 2023

REP-GB-17047

300 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -